Güldoğan Cem Emir, Kılıç Murat Özgür, Balamir İlhan, Tez Mesut, Turhan Turan
Department of General Surgery, Numune Training and Research Hospital, Ankara-Turkey.
Ulus Travma Acil Cerrahi Derg. 2017 Nov;23(6):472-476. doi: 10.5505/tjtes.2017.51499.
Although Ranson score is the most commonly used prognostic model in the severity of acute pancreatitis (AP), ischemia-modified albumin (IMA) has been reported as a novel biomarker of various ischemia-based diseases in recent years. The aim of the present study is to investigate the correlation between Ranson score and IMA in patients with AP.
Forty-three patients with AP were included in the study. All patients were classified as mild and severe AP. Plasma IMA level was measured after diagnosis and before treatment. The correlation between IMA level and amylase level, Ranson score, and disease severity was evaluated.
Twenty-nine (67.4%) patients were diagnosed as mild AP; the remaining 14 (32.6%) patients had moderately severe or severe form of disease, and were classified as severe AP. There was no significant difference in the IMA levels between the patient groups (p=0.737). No correlation between IMA levels and amylase levels (p=0.470), Ranson score (p=0.664), and disease severity (p=0.741) was found.
According to the results from the study, IMA does not seem as a useful marker in earlier prediction of disease severity in AP. Despite important disadvantages, Ranson score still indicates the disease severity more accurately.
尽管兰森评分是急性胰腺炎（AP）严重程度最常用的预后模型，但近年来，缺血修饰白蛋白（IMA）已被报道为各种缺血性疾病的新型生物标志物。本研究的目的是探讨AP患者中兰森评分与IMA之间的相关性。
本研究纳入了43例AP患者。所有患者均分为轻度和重度AP。在诊断后和治疗前测量血浆IMA水平。评估IMA水平与淀粉酶水平、兰森评分和疾病严重程度之间的相关性。
29例（67.4%）患者被诊断为轻度AP；其余14例（32.6%）患者患有中度或重度疾病，被归类为重度AP。患者组之间的IMA水平无显著差异（p=0.737）。未发现IMA水平与淀粉酶水平（p=0.470）、兰森评分（p=0.664）和疾病严重程度（p=0.741）之间存在相关性。
根据研究结果，IMA似乎不是AP疾病严重程度早期预测的有用标志物。尽管存在重要缺点，但兰森评分仍能更准确地指示疾病严重程度。
